Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

A Vigani

Showing results (1-10 of 34) with videos related to

Pageof 4
Sort By:
The Veterinary Record|August 25, 2009
Uncommon mediastinal cyst-like manifestation of feline infectious peritonitisA Vigani, A Giordano, O Travetti
British Journal of Cancer|June 1, 1996
A feasibility study of accelerated polychemotherapy with cisplatin, epidoxorubicin and cyclophosphamide (PEC) in advanced ovarian cancerP Pronzato, G Bertelli, A Vigani, et al.
Tumori|January 31, 1998
[Low-dose GM-CSF and dose intensity of antineoplastic agents]P Pronzato, F Pensa, F Vaira, et al.
Oncology Reports|May 20, 2011
Tropisetron-dexamethasone combination for carboplatin-induced emesisP Pronzato, E Ghio, P Losardo, et al.
Journal of Chemotherapy (Florence, Italy)|August 28, 1998
A dose finding study for the combination of epidoxorubicin and vinorelbine, delivered every two weeks with G-CSF support, in advanced breast cancerP Pronzato, A Tognoni, F Pensa, et al.
Oncology Reports|May 20, 2011
Interleukin-2 and interferon alpha 2 combinationP Pronzato, A Vigani, F Vaira, et al.
Chemotherapy|March 1, 1994
Carboplatin and etoposide as outpatient treatment of advanced non-small-cell lung cancerP Pronzato, M Landucci, F Vaira, et al.
Anticancer Research|November 1, 1995
Biochemical modulation of 5-fluorouracil with methotrexate in advanced colorectal cancer patients pretreated with adjuvant 5-fluorouracil and leucovorinP Pronzato, F Vaira, A Vigani, et al.
Lung Cancer (Amsterdam, Netherlands)|December 18, 2001
Anthracyclines in non-small cell lung cancerP Pronzato, A Vigani, A Tognoni, et al.
European Journal of Cancer (Oxford, England : 1990)|January 1, 1994
Mitoxantrone and 5-fluorouracil modulated by the pure (6S) stereoisomer of leucovorin as second-line chemotherapy for advanced breast cancerP Pronzato, G Bertelli, F Vaira, et al.
Pageof 4

Showing results (1-10 of 34) with videos related to

Sort By:
Pageof 4
The Veterinary Record|August 25, 2009
Uncommon mediastinal cyst-like manifestation of feline infectious peritonitisA Vigani, A Giordano, O Travetti
British Journal of Cancer|June 1, 1996
A feasibility study of accelerated polychemotherapy with cisplatin, epidoxorubicin and cyclophosphamide (PEC) in advanced ovarian cancerP Pronzato, G Bertelli, A Vigani, et al.
Tumori|January 31, 1998
[Low-dose GM-CSF and dose intensity of antineoplastic agents]P Pronzato, F Pensa, F Vaira, et al.
Oncology Reports|May 20, 2011
Tropisetron-dexamethasone combination for carboplatin-induced emesisP Pronzato, E Ghio, P Losardo, et al.
Journal of Chemotherapy (Florence, Italy)|August 28, 1998
A dose finding study for the combination of epidoxorubicin and vinorelbine, delivered every two weeks with G-CSF support, in advanced breast cancerP Pronzato, A Tognoni, F Pensa, et al.
Oncology Reports|May 20, 2011
Interleukin-2 and interferon alpha 2 combinationP Pronzato, A Vigani, F Vaira, et al.
Chemotherapy|March 1, 1994
Carboplatin and etoposide as outpatient treatment of advanced non-small-cell lung cancerP Pronzato, M Landucci, F Vaira, et al.
Anticancer Research|November 1, 1995
Biochemical modulation of 5-fluorouracil with methotrexate in advanced colorectal cancer patients pretreated with adjuvant 5-fluorouracil and leucovorinP Pronzato, F Vaira, A Vigani, et al.
Lung Cancer (Amsterdam, Netherlands)|December 18, 2001
Anthracyclines in non-small cell lung cancerP Pronzato, A Vigani, A Tognoni, et al.
European Journal of Cancer (Oxford, England : 1990)|January 1, 1994
Mitoxantrone and 5-fluorouracil modulated by the pure (6S) stereoisomer of leucovorin as second-line chemotherapy for advanced breast cancerP Pronzato, G Bertelli, F Vaira, et al.
Pageof 4